DXR
HoldSinkerDaxor Corporation · Healthcare · United States · $60M · Avg Vol: $318K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT DAXOR CORPORATION
Read
Daxor Corporation is a medical instrumentation and biotechnology company specializing in blood volume measurement technology. The company's competitive moat is anchored by its BVA-100 (Blood Volume Analyzer), which is the only FDA-cleared diagnostic device capable of directly and accurately measuring a patient's total blood volume. Daxor operates as a unique niche player, with its technology increasingly adopted in intensive care units to guide fluid management for heart failure and sepsis patients.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 6.3M | 1.3M | 2.1M | 10.3M | 17.8% | — | 9.3M | 16.4M | 26.2% |
| EPS | — | 0.87 | 0.14 | -0.09 | 1.64 | 23.5% | 1.69 | — | — | — |
| Shares | — | 4.3M | 4.8M | 4.9M | 5.1M | +17.9% | 5.8M | — | — | — |
| Debt | 3.0M | 1.2M | 0.8M | 0.7M | — | -37.7% | — | — | — | — |
| Equity | — | 29.0M | 34.0M | 35.8M | 45.9M | 16.6% | — | — | — | — |
| Op CF | — | -0.8M | -3.7M | 25.7K | 0.6M | 2122.2% | -8.2M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — | — | — |
| Fin CF | — | 58.6K | 3.7M | -25.7K | -0.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DXR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DXR | Daxor Corporation(you) | $60M | 50 | Hold |
| KRMD | KORU Medical Systems, Inc. | $148M | 25 | Sell |
| OSUR | OraSure Technologies, Inc. | $248M | 33 | Sell |
| ANGO | AngioDynamics, Inc. | $655M | 52 | Hold |
| SMTI | Sanara MedTech Inc. | $318M | 68 | Buy |
| STXS | Stereotaxis, Inc. | $145M | 5 | Strong Sell |
| STAA | STAAR Surgical Company | $1.1B | 57 | Hold |
| AZTA | Azenta, Inc. | $1.4B | 46 | Hold |
| BLFS | BioLife Solutions, Inc. | $1.8B | 50 | Hold |
| EMBC | Embecta Corp. | $286M | 88 | Strong Buy |
Peer medians: ROE -31.0% · P/E 25.2x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.